Saul A. Rosenberg

Saul A. Rosenberg's AcademicInfluence.com Rankings

Saul A. Rosenberg

Philosophy

#6545

World Rank

#9596

Historical Rank

Logic

#3697

World Rank

#4894

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Saul A. Rosenberg's Degrees

Doctorate Medicine Harvard University

Why Is Saul A. Rosenberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Saul A. Rosenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. (1989) (1526)
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. (1984) (906)
Non‐hodgkin's lymphomas iv. clinicopathologic correlation in 405 cases (1973) (578)
The grading of soft tissue sarcomas results of a clinicohistopathologic correlation in a series of 163 cases (1984) (490)
Hematologic neoplasia in patients treated for Hodgkin's disease. (1977) (428)
The value of laparotomy and splenectomy in the staging of Hodgkin's disease (1969) (397)
Central nervous system involvement in non‐Hodgkin's lymphoma: An analysis of 105 cases (1982) (327)
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. (1997) (326)
Report of the Committee on the Staging of Hodgkin's Disease (1966) (322)
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. (2002) (317)
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. (1999) (316)
Intratumoral LAK cell and interleukin-2 therapy of human gliomas. (1989) (251)
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. (1996) (246)
Evidence for an orderly progression in the spread of Hodgkin's disease. (1966) (235)
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. (1999) (229)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. (2013) (228)
Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. (2004) (228)
Histologic conversion in the non-Hodgkin's lymphomas. (1983) (211)
Report of the Committee on Hodgkin's Disease Staging Procedures. (1971) (209)
The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. (1984) (208)
Immune selection after antigen-specific immunotherapy of melanoma. (1999) (186)
Analysis of non‐Hodgkin's lymphomas with nodular and favorable histologies, stages I and II (1983) (161)
Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas. (1977) (159)
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. (2001) (156)
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. (1970) (150)
Non‐Hodgkin's lymphomas. II. Single agent chemotherapy (1972) (150)
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. (1995) (145)
Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. (1984) (143)
Spontaneous regression of non‐Hodgkin's lymphoma: A report of nine cases (1980) (142)
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. (1996) (142)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Non‐Hodgkin's lymphomas. V. Results of radiotherapy (1973) (138)
Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. (1998) (135)
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. (1996) (135)
Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) (1978) (130)
Treatment of Hodgkin lymphoma: a 50-year perspective. (2014) (127)
Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial (1976) (123)
Staging laparotomies in unselected previously untreated patients with non‐Hodgkin's lymphomas (1973) (122)
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). (1986) (122)
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. (2000) (113)
Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. (1966) (112)
The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy (1975) (110)
Extralymphatic involvement in diffuse non-Hodgkin's lymphoma. (1983) (106)
Non‐Hodgkin's lymphomas. I. Bone marrow involvement (1972) (106)
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. (1997) (105)
Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. (1998) (100)
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial (1985) (97)
Combined modality therapy of Hodgkin's disease. A report on the stanford trials (1978) (97)
Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities. (1985) (97)
Pediatric Hodgkin's disease. II. Results of therapy (1976) (93)
Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. (1973) (93)
Management of the pregnant patient with Hodgkin's disease. (1981) (92)
The Low-Grade Non-Hodgkin's Lymphomas: Challenges and Opportunities (1985) (92)
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. (1997) (92)
Current concepts in cancer: non-Hodgkin's lymphoma--selection of treatment on the basis of histologic type. (1979) (90)
Prognostic factors in pathological stage IIIA Hodgkin's disease (1980) (89)
Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experience (1980) (89)
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. (2013) (88)
Treatment of lymphoblastic lymphoma in adults. (1986) (86)
Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. (1988) (86)
A critique of the value of laparotomy and splenectomy in the evaluation of patients with Hodgkin's disease. (1971) (85)
Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment (1976) (81)
Hodgkin's disease and other malignant lymphomas. (1970) (74)
Hodgkin's disease of the bone marrow. (1971) (70)
The management of Hodgkin's disease (1975) (68)
The effect of intravenous interleukin-2 on brain water content. (1989) (68)
Non‐Hodgkin's lymphomas. VI. Results of treatment in childhood (1974) (68)
Lymphoblastic lymphoma in adults: results of a pilot protocol. (1981) (67)
MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients (1973) (65)
Treatment of advanced Hodgkin's disease with B‐CAVe following MOPP failure (1978) (63)
Lymphomas involving the gastrointestinal tract (1982) (62)
Infections in patients with Hodgkin's disease: a clinical study of 300 consecutive adult patients. (1980) (60)
Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non‐Hodgkin's lymphomas (1976) (57)
Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease (1979) (56)
Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy (1978) (54)
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. (2007) (49)
Hodgkin's disease limited to intrathoracic sites (2006) (48)
Medical Oncology: Basic Principles and Clinical Management of Cancer (1993) (47)
Combined modality therapy in malignant lymphomas. (1977) (46)
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma (1990) (43)
The treatment of Hodgkin's disease. (1966) (42)
Combination chemotherapy and radiotherapy for Hodgkin's disease (1972) (42)
Hodgkin's disease, stages I and II occurring below the diaphragm (1979) (40)
Pathology of malignant lymphomas in the liver: application in staging. (1976) (40)
The management of Hodgkin's disease: half a century of change. The Kaplan Memorial Lecture. (1996) (36)
Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary results. (1975) (35)
The value of sequential bone marrow biopsy and laparotomy and splenectomy in a series of 127 consecutive untreated patients with non-Hodgkin's lymphoma. (1975) (32)
Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. (1999) (32)
Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients. (2004) (31)
A STUDY OF THE ETIOLOGICAL BASIS OF PRIMARY PULMONARY HYPERTENSION. (1964) (27)
Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment (1982) (27)
Clinical aspects of non‐Hodgkin's lymphomas presenting with discordant histologic subtypes (1983) (25)
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. (1990) (25)
Single agent palliative chemotherapy for end‐stage Hodgkin's disease (1982) (24)
A summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University. (1975) (24)
The bcl-2 gene, follicular lymphoma, and Hodgkin's disease. (1990) (22)
Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy. (1990) (22)
The treatment of Hodgkin's disease. (1966) (21)
Hodgkin's disease: challenges for the future. (1989) (21)
Extralymphatic Hodgkin's disease. Prognosis and response to therapy. (1981) (20)
Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor. (1990) (20)
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells (2003) (19)
Late relapse from complete remission in nodular and diffuse histiocytic lymphoma (1983) (18)
Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. (1999) (18)
Exploratory laparotomy and splenectomy for Hodgkin's disease: a commentary. (1988) (18)
Initial relapse in previously treated Hodgkin's disease--II retrograde transdiaphragmatic extension. (1977) (17)
Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: diagnostic and therapeutic challenges (2006) (17)
The management of Hodgkin's disease. (1978) (17)
Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003. (2007) (16)
Splenectomy In The Management Of Hodgkin's Disease (1972) (16)
The continuing challenge of Hodgkin's disease. (1991) (15)
The Clinical Evaluation and Staging of Patients with Malignant Lymphoma (1971) (15)
The value of sequential bone marrow biopsy and laparotomy and splenectomy in a series of 200 consecutive untreated patients with non-Hodgkin's lymphoma. (1979) (14)
Nasogastric tube perforation of the nasopharynx. (1985) (14)
Management of the Pregnant Patient with Hodgkinʼs Disease (1982) (14)
Correction: Deaths after Treatment of Hodgkin Disease (1991) (14)
Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. (2009) (14)
Follicular lymphoma revisited. (2008) (13)
Laparotomy and splenectomy in Hodgkin's disease: a reappraisal after twenty years. (2009) (12)
Lymphomas involving the gastrointestinal tract. (1982) (12)
Non-Hodgkin's lymphomas. 3. Preliminary results of radiotherapy and a proposal for new clinical trials. (1972) (11)
Bone marrow involvement in the non-Hodgkin's lymphomata. (1975) (11)
Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. (2009) (11)
Pediatric hodgkin's disease. II. Results of therapy. (1976) (11)
Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. (2011) (11)
Autologous bone marrow transplantation in non-Hodgkin's lymphoma. (1987) (11)
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. (1996) (8)
THE RESULTS OF RADICAL RADIOTHERAPY IN HODGKIN'S DISEASE AND OTHER LYMPHOMAS. (1969) (8)
Extended-field radiation therapy in Hodgkin's disease. A progress report. (1968) (7)
Reducing the toxicity of the combined modality therapy of favourable stage Hodgkin's disease. (1992) (7)
Staging in adult non-Hodgkin's lymphomas. (1978) (7)
Lymphography: a great advance, abandoned. (2008) (6)
A rare type of Hodgkin's disease. (1973) (6)
Cure of Hodgkin's disease and other malignant lymphomas. (1968) (6)
Place of Splenectomy in Evaluation and Management (1972) (6)
The current status of the Stanford randomized clinical trials of the management of Hodgkin’s disease (1985) (6)
ABVD versus MOPP: which is better? (1987) (5)
Staging of Hodgkin's Disease (1966) (5)
Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin’s Disease (HD); the Stanford V + Radiotherapy (RT) Experience. (2005) (5)
The role of chemotherapy in the management of early stage Hodgkin's disease (1984) (5)
Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. (2011) (5)
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. (2014) (5)
Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. (1993) (5)
A prospective trial of involved field radiation (IFRT) + chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy (2007) (5)
International Symposium on Hodgkin's Disease. Session 5. Treatment. Current status of clinical trials: Stanford experience, 1962-72. (1973) (4)
Rare presentation of classical Hodgkin lymphoma with a clonal T-cell receptor gene rearrangement in the tissue (2010) (4)
Modern combined modality management of Hodgkin's disease (1994) (4)
Kinetics of T cell receptor utilization in response to repeated epitope-specific immunization (2001) (4)
Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies). (2020) (3)
History of Radiotherapy of Hodgkin’s Disease (Now Hodgkin Lymphoma) (2011) (3)
Long-term outcomes of patients with unfavorable stage I–II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation (2020) (3)
THE RELATIVE CLINICAL VALUE OF THE VARIOUS CLASSIFICATIONS OF HUMAN NON-HODGKIN'S LYMPHOMAS (1982) (2)
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 (2008) (2)
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma (2016) (2)
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. (2018) (2)
The Results of the Treatment of Hodgkin’s Disease: An Overview of Current Approaches and Future Directions (1980) (2)
REPORT ON WORKSHOP SESSION. CLINICAL EVALUATION, STAGING, AND PROGNOSIS. (1972) (2)
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. (2009) (2)
Hodgkin's disease: current status and future challenges. (1980) (1)
Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience. (2010) (1)
Hodgkin's disease: Current recommendations for management (1975) (1)
Cardiovascular mortality following treatment of Hodgkin's disease (1989) (1)
The Paris conference "La Radiothérapie de la Maladie de Hodgkin": a first step in the cure of Hodgkin disease. (2015) (1)
The treatment of stage III – IV non-Hodgkin'S lymphoma of “favorable” histologic type. A randomized comparison of whole body irradiation, combination chemotherapy, and single agent chemotherapy (1979) (1)
Stage I/II Hodgkin’s Disease: Comparison of Outcomes of Patients with Bulky Mediastinal Disease Versus Other Risk Factors; the Stanford V Experience. (2007) (1)
[Segmentary radiotherapy of Hodgkin's disease. 1st results of 2 controlled therapeutic trials]. (1966) (0)
[PRESENTATION OF THE RADIOTHERAPEUTIC TRIAL PRECEDURE FOR MALIGNANT LYMPHOMAS OF STANFORD UNIVERSITY]. (1964) (0)
Radiotherapy for Hodgkin's disease questioned. (1968) (0)
combined modality therapy: the Stanford experience The management of stage I--II Hodgkin's disease with irradiation alone or (2011) (0)
The effect of prior sedation on nitrogen mustard effect in the rat. (1962) (0)
Outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the pre- and post-rituximab era: The Stanford University experience. (2011) (0)
Clinical Relevance of Morphologic Studies in Hodgkinʼs Disease (1987) (0)
Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease (2010) (0)
Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen (2010) (0)
Letter: Prevention of adhesion recurrence after adhesiolysis. (1975) (0)
The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation (2018) (0)
Updated Hodgkin's disease. Place of splenectomy in evaluation and management. (1972) (0)
necrosis factor-alpha in response to autologous tumor stimulation secrete granulocyte-macrophage colony-stimulating factor and tumor Tumor-infiltrating lymphocytes derived from select B-cell lymphomas (2011) (0)
MOPP after two decades. (1986) (0)
[Clinical classification of Hodgkin's disease. Its importance and the influence of general signs]. (1966) (0)
An Evaluation Of Abdominal Ct Scanning In Initial Staging Of Hodgkin's And Non-hodgkin's Lymphoma: Progress Report (1981) (0)
Intercurrent death following Hodgkin's disease therapy: radiotherapy, adjuvant mopp trials (1987) (0)
Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease (2010) (0)
Comments on “Clinical Aspects: Staging and Therapeutic Implications” (1978) (0)
Combination chemotherapy in Hodgkin's disease: relation to radiotherapy. (1975) (0)
The Cure of Malignant Lymphomas (1968) (0)
Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy (2018) (0)
The low grade non-Hodgkin’s lymphomas: Current approaches to therapy (1985) (0)
A simple test to determine the site of bleeding in the upper part of the gastrointestinal tract. (1976) (0)
Treatment of Primary Neoplasms of Lymphoid Tissues (1978) (0)
Prognostic factors after relapse in non-Hodgkin's lymphoma of favorable histologic type (1980) (0)
[Recommendations for therapy of lymphogranuloma]. (1976) (0)
The malignant lymphomas called “non-Hodgkin's”: Thirty years of learning more and knowing less (1991) (0)
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. (2009) (0)
No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission (2018) (0)
Clinical Manifestations, Staging, and Management of the Non-Hodgkin’s Lymphomas: An Overview (1980) (0)
Changing Concepts in Therapy of the Non-Hodgkin Lymphomas (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Saul A. Rosenberg?

Saul A. Rosenberg is affiliated with the following schools:

Stanford University